REG - Verici Dx PLC - Transfer of urine samples to Thermo Fisher

Verici DxAnnouncement

18/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240618:nRSR7733Sa&default-theme=true

RNS Number : 7733S  Verici Dx PLC  18 June 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Transfer of urine samples to Thermo Fisher Scientific

Following completion of the transfer, full payment has been received

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces it has completed successful transfer of a portion
of the Company's urine samples as announced as part of the global
commercialisation and licensing agreement announced in November 2023(1). As
previously stated, it demonstrates the additional value in the Company's data
and sample assets for research.

 

Sara Barrington, CEO, said:

 

"We are delighted to announce the successful completion of this transfer,
within the agreed timeline. This achievement not only highlights our
commitment to delivering on our agreements, but also underscores the
substantial value inherent in the Company's data and sample assets for
research purposes."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 

 

Notes

1.     Please refer to RNS number 4652T for further information. A copy of
this announcement can also be found on the company website
https://verici-dx-plc.flint-platform.com/regulatory-news/44270
(https://verici-dx-plc.flint-platform.com/regulatory-news/44270)

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQDLFFZQLEBBK